1 / 1

Cibinqo(abrocitinib)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Pfizer Inc.

Formulation:

TABLET

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Cibinqo(abrocitinib) Instructions:Uses,Dosage, Side Effects

Abrocitinib was developed by Pfizer, a globally renowned biopharmaceutical company committed to providing innovative therapeutic solutions in the field of health. Abrocitinib was approved for marketing in Japan and the European Union in September and December 2021, respectively, for the treatment of moderate-to-severe atopic dermatitis. On January 14, 2022, abrocitinib was approved for marketing in the United States with recommended dosages of 100 mg and 200 mg, having previously received FDA Breakthrough Therapy and Priority Review designations.

On April 11, 2022, abrocitinib was approved for marketing in China by the National Medical Products Administration and has been included in the national medical insurance reimbursement program. In China, abrocitinib is classified as a Class B drug under the medical insurance policy, meaning it is covered by China's medical insurance system.

Generic name

Cibinqo(abrocitinib)

English name

Cibinqo

Alternative Names

abrocitinib

Drug prices

Indications

Abrocitinib tablets are a Janus kinase (JAK) inhibitor indicated for the treatment of adults and pediatric patients aged 12 years and older with refractory moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products (including biologics) or for whom these therapies are not advisable.

Use Restriction: Co-administration of abrocitinib tablets with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants is not recommended.

Therapeutic Target

JAK1

Active Ingredients

abrocitinib

Dosage form

TABLET

specifications

100mg*14 tablets/bottle

Description

Dosage and Administration

The recommended dosage is 100 mg once daily. If 100 mg of abrocitinib tablets once daily does not achieve an adequate response, consider increasing the dosage to 200 mg once daily. If 200 mg once daily does not achieve an adequate response, discontinue the drug. Use the minimum effective dose to maintain the response.

Abrocitinib tablets can be used with or without topical corticosteroids. If a dose is missed, administer it as soon as possible unless it is less than 12 hours until the next dose, in which case the missed dose should be skipped. Thereafter, resume administration at the specified time.

CATEGORY NAVIGATION